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Abstract
Feline immunodeficiency virus (FIV) infection like human immunodeficiency virus (HIV),
produces systemic and central nervous system disease in its natural host, the domestic cat, that
parallels the pathogenesis seen in HIV-infected humans. The ability to culture feline nervous
system tissue affords the unique opportunity to directly examine interactions of infectious virus
with CNS cells for the development of models and treatments that can then be translated to a
natural infectious model. To explore the therapeutic potential of a new p75 neurotrophin receptor
ligand, LM11A-31, we evaluated neuronal survival, neuronal damage and calcium homeostasis in
cultured feline neurons following inoculation with FIV. FIV resulted in the gradual appearance of
dendritic beading, pruning of processes and shrinkage of neuronal perikarya in the neurons.
Astrocytes developed a more activated appearance and there was an enhanced accumulation of
microglia, particularly at longer times post-inoculation. Addition of 10 nM LM11A-31, to the
cultures greatly reduced or eliminated the neuronal pathology as well as the FIV effects on
astrocytes and microglia. LM11A-31 also, prevented the development of delayed calcium
deregulation in feline neurons exposed to conditioned medium from FIV treated macrophages.
The suppression of calcium accumulation prevented the development of foci of calcium
accumulation and beading in the dendrites. FIV replication was unaffected by LM11A-31. The
strong neuroprotection afforded by LM11A-31 in an infectious in vitro model indicates that
LM11A-31 may have excellent potential for the treatment of HIV-associated neurodegeneration.
Introduction
Human immunodeficiency virus (HIV) infects macrophages and microglia in the central
nervous system (CNS) resulting in, inflammation and the gradual development of a range of
cognitive-motor deficits. Although combination antiretroviral therapy (CART) has
decreased the severity of neurological symptoms, CNS disease continues to progress
Corresponding Author: Rick B Meeker, Department of Neurology, CB #7025, 6109F Neuroscience Research Building, 115 Mason
Farm Road, University of North Carolina, Chapel Hill, NC 27599, Phone: 919-966-5512, meekerr@neurology.unc.edu, FAX:
919-843-4676.
2Current Address: Research Triangle Institute, Research Triangle Park, NC 27709
3Current address: State Key Laboratories for Agrotechnobiology, China Agricultural University, Beijing, China
conflict of interest
Dr. Longo is founder of PharmatrophiX Inc., a company focused on the development of neurotrophin ligands including LM11A-31.
Other authors have no affiliation with PharmatrophiX Inc.
NIH Public Access
Author Manuscript
J Neuroimmune Pharmacol. Author manuscript; available in PMC 2013 August 19.
Published in final edited form as:













(2Sacktor et al., 2002; Brew, 2004) and evolve into different types of pathology (Masliah et
al., 1997; Langford et al., 2003). Interventions are needed to suppress neuropathogenesis
which, if unchecked, is expected to support an increasing neurological disease burden.
To develop therapies that prevent CNS damage in HIV-infected patients we need a better
understanding of the underlying neuropathogenesis, particularly during early stages where
interventions are likely to have the greatest impact. Animal models have provided essential
tools to explore the pathogenesis in both in vivo and in vitro systems. While each of the
various animal models allows the opportunity to explore specific contributions to
pathogenesis, only two represent natural infections that recapitulate disease progression in
HIV-infected humans, simian immunodeficiency virus (SIV) and feline immunodeficiency
virus (FIV). Our studies have focused on the use of the FIV model in an effort to develop
parallel in vitro and in vivo approaches that identify pathogenic mechanisms and support the
testing of interventions in infected cats.
The FIV model recapitulates much of the pathogenesis seen with HIV. It primarily infects
CD4+ Tcells and cells of monocyte lineage(Brunner and Pedersen, 1989; Brown et al.,
1991; English et al., 1994; Dow et al., 1999) eventually causing immunodeficiency and CNS
disease(Pedersen et al., 1987; Sparger et al., 1989; Podell et al., 1993; English et al., 1994;
Phillips et al., 1994). FIV rapidly penetrates the brain (Ryan et al., 2003; Liu et al., 2006)
where it establishes an infection (Dow et al., 1990) and leads to neuropathogenesis(Dow et
al., 1990; Hurtrel et al., 1992; Meeker et al., 1997). Like HIV, interactions with
macrophages and microglia result in inflammation and the release of factors that damage
neurons(Bragg et al., 2002) resulting in neuropathological changes similar to HIV but
typically less severe, including a diffuse gliosis, microglial nodules, meningitis, perivascular
infiltrates, white matter lesions and neuronal loss; (Hurtrel et al., 1992; Phillips et al., 1994;
Meeker et al., 1997). Cortical atrophy has been demonstrated by MRI(Podell et al., 1993).
Key elements of the neuropathogenesis of FIV can be modeled in vitro. Feline neurons in
mixed neural cultures inoculated with FIV have enhanced sensitivity to glutamate-induced
calcium accumulation and damage (Meeker et al., 1996; Meeker, 2007). Toxins secreted
from feline macrophages induce a delayed calcium deregulation and neural damage(Bragg et
al., 2002) due, in part, to the suppression of intracellular calcium recovery (Bragg et al.,
2002).
In the present studies we used the FIV model to explore the neuroprotective efficacy of a
new neurotrophin ligand, LM11A-31, that targets the p75 neurotrophin receptor (p75NTR)
(Longo and Massa, 2008). LM11A-31 was developed as a small molecule ligand to mimic
loop 1 of nerve growth factor (Massa, et al, 2006). It competes for binding to p75NTR but
not TrkA and increases NFkB phosphorylation and Akt activation in a p75NTR-dependent
fashion (Massa, et al, 2006). It does not have the pro-apoptotic actions that can be mediated
by pro-NGF(Massa, et al, 2006). The neuroprotective actions are unique from NGF since it
offers protection from Aβ-induced neuron death where NGF is ineffective (Knowles, et al,
2008). The potential utility of this ligand for HIV infection was suggested by observations of
altered neurotrophin signaling in infected patients. Brain-derived neurotrophic factor
(BDNF) and its receptor, TrkB, are increased in HIV-infected brain(Soontornniyomkij et al.,
1998) (and BDNF and nerve growth factor (NGF) protect neurons against Tat- (Ramirez et
al., 2001) and gp120-mediated apoptosis(Mocchetti and Bachis, 2004; Bachis and
Mocchetti, 2005; Nosheny et al., 2005). The neurotrophins may provide broad natural
protection by suppressing or counteracting several destructive processes triggered by gp120
and Tat such as pro-apoptotic signaling cascades(Kruman et al., 1998; Garden et al., 2002),
interference with NGF signaling(Peruzzi et al., 2002) and activation of p38 MAPK, p53 and
glycogen synthase kinase-3β(GSK-3β)(Maggirwar et al., 1999; Kaul et al., 2001). The
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following studies examined the potential of LM11A-31 to protect cultured neurons from the
damaging effects of FIV and associated macrophage toxins.
Materials and Methods
Neural cultures
Neural cultures were prepared from the forebrain of E30–45 fetuses removed during spays
of pregnant cats. The protocol for removal and culture of fetal material followed institutional
and federal guidelines and was approved by the North Carolina State University College of
Veterinary Medicine Institutional Animal Care and Use Committee. After removal, the
uterus was placed on ice and transported to the tissue culture facility where the fetuses were
removed and placed in ice cold HEPES-buffered Hank’s balanced salt solution (HBSS). The
brain was harvested from each fetus, rinsed three times in fresh sterile HBSS and the
forebrain containing the cortex, hippocampus and basal ganglia transferred to a 15 ml tube
containing calcium-magnesium free HBSS (CMF-HBSS), 1.25 U/ml dispase II + 2 U/ml
DNase I. After incubation for 25–30 min at 37° C the cells were gently dissociated by
several rounds of trituration and collected in a tube containing 25 mls Minimum Essential
Medium (MEM) with glutamine plus 10% fetal bovine serum and 20 μg/ml gentamicin
(complete medium). The dissociated cells were seeded into poly-D-lysine-coated culture
dishes at a density of 50,000 – 100,000 cells/cm2 for toxicity analysis or 25,000 cells/cm2 on
poly-D-lysine-coated coverslips for imaging. Cultures were fed by 50% exchange of
complete medium three times per week. Cells were allowed to grow at least 6 days in vitro,
at which time they contain an enriched population of neurons (>80%). Over the next week,
the cultures slowly become populated with astrocytes. Imaging studies were done prior to
extensive outgrowth of the astrocytes at 6–12 days in cultures where fields of isolated
neurons could be obtained
Cultures were infected with FIV at times ranging from 6–12 days in vitro for neuronal
cultures depending on the experiment. Cultures were not washed following inoculation to
facilitate prolonged exposure to the virus with the exception of the infection studies where
the cultures were washed five times at 4 hours after inoculation. Viral titers were selected to
reflect the high range of virus seen in CSF in vivo (104 – 106 copies/ml).
To assess neurotrophic activity, feline neurons were seeded at very low densities of 2800–
4000 cells/cm2. Survival is typically low at this density but can be improved by
neurotrophins. Survival over time was monitored under phase contrast and cells with
neuronal morphology and distinctive neurite outgrowth were counted. Final survival and
elaboration of processes was evaluated by staining with the neuron marker microtubule
associated protein-2 (MAP-2).
Sources of FIV
Two strains of FIV were used in these studies. FIVNCSU1 was isolated from a naturally
infected cat with lymphopenia and acute enteritis. Peripheral blood mononuclear cells from
this cat were used to inoculate 2 purpose bred specific pathogen free cats. Pooled PBMC
from these 3 donor cats were co-cultured with a CD4+ lymphocyte cell line (FCD4-E), and
high RT activity supernatant collected and frozen as a source of virus stock. Intravenous and
intracerebroventricular inoculation of cats results in robust infection, with a persistent
decrease in the CD4:CD8 ratio and a gradual loss of CD4+ T cells(English et al., 1994;
Meeker et al., 1997; Liu et al., 2006). Both anti-FIV antibodies and FIV provirus are present
by 2 to 4 weeks p.i. as detected by ELISA and PCR amplification, respectively. The virus
infects both CD4+ T cells and monocyte/macrophages. In addition, an FIV strain with
enhanced neurotropism (FIVV1CSF) isolated from the CSF of a cat with neurological
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disease(Power et al., 1998; Johnston et al., 2002) was used to enhance neurovirulence. To
maximize infection of cultures and neurovirulence, a 1:1 mix of viruses was used as the
challenge.
Conditioned medium from feline choroid plexus macrophages
Cultures of purified macrophages were prepared from fetal choroid plexus. Choroid plexus
was removed from the lateral ventricles of fetal brains at 30–62 days gestation as described
above for neural cultures. The choroid plexus was washed extensively and placed into 6-
well low adhesion plates (approximately 6/well) containing Dulbecco’s Modified Eagle
Medium (DMEM), supplemented with 10% fetal bovine serum (FBS) and 20 μg/ml
gentamicin (complete medium). The cultures were maintained in a 5% CO2 incubator at 36°
C. Over a period of approximately one week, macrophages replicate and migrate from the
choroid plexus. The macrophages were the only cells that attached to the low adhesion
plastic giving rise to a pure population of macrophages. The cultures were initially fed by
supplementing the medium with fresh medium (twice) and then were fed three times a week
by carefully aspirating medium from the surface (avoiding removal of the choroid plexus
explants) and replacing with fresh medium. After 8–12 days in culture, choroid plexus
cultures were typically enriched in macrophages at densities ranging from approximately 50
– 170 cells/mm2 (40,000–136,000/well). The choroid plexus was then removed and the
macrophages washed with fresh medium. The resulting cultures were conservatively >95%
macrophages. These macrophages were then infected with FIV at an MOI of 1 in 1.2 mls of
complete DMEM. Medium from these cells was harvested after 3 days and ultrafiltered at
300 kDa to remove virus. Medium collected from the same cells prior to infection was
collected as a control. Conditioned medium was aliquoted and stored frozen at −80° until
used for toxicity testing.
Real Time PCR quantification of FIV
Viral RNA was extracted from samples using QIAamp Viral RNA Mini Kit (Qiagen, CA).
The viral RNA loads were determined by real time RT-PCR with the Taqman onestep RT-
PCR master kit (Applied Biosystems, CA). The following specific primers and probe of FIV
gag region were used which recognize both NCSU1 and V1CSF variants: FIVNC-491F (5′-
GATTAGGAGGTGAGGAA GTTCA GCT–3′), FIVNC-617R (5′-
CTTTCATCCAATATTTCTTTATCTGCA–3′) and the labeled probe, FIVNC-555p (5′-
FAM- CATGGCCACATTAATAATGG CGCA -TAMRA-3′ (Applied Biosystems, CA).
These reactions were performed with a Bio-Rad iCyclerTM iQ and analyzed using the
manufacturer’s software. A standard curve was generated within each run from dilutions of
an FIV standard of known copy numbers.
Immunocytochemistry
Neurons were identified by microtubule-associated protein-2 (MAP-2) immunostaining.
Cells were fixed in ice cold 97% methanol, 3% acetic for 10 min at room temperature and
washed in 0.01 M phosphate-buffered saline (PBS, 3 × 5 min). Cells were incubated in
blocking buffer containing 3% normal goat serum in 0.01 M PBS for 60 min at room temp.
Polyclonal rabbit anti-MAP-2 (Chemicon/Millipore, Bilerica, MA) was then applied at a
dilution of 1:500 in blocking buffer and incubated overnight at 4° C. The cells were washed
three times in PBS and incubated in goat anti-rabbit Alexa488 (1:500) or mouse anti-rabbit
Alexa568 (1:500) for 1 h. The cells were washed three times in PBS. Astrocytes were
stained in a similar fashion using 1:500 rabbit anti-GFAP (DAKO). Nuclei were
counterstained with bisbenzimide (0.5 μM, Sigma Corp, St Louis, MO) for 20 min in PBS,
washed 2 × 5 min and the coverslips were mounted onto slides with Fluoromount (Southern
Biotech, Birmingham AL).
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Staining was examined with an Olympus IMT-2 or Olympus IX71 inverted microscope and
quantified with digital imaging and Metamorph imaging software. Neuron survival was
measured by counting the number of viable neurons in five fields. Neuron morphology was
evaluated by measuring the microtubule-associated protein-2 (MAP-2) fluorescence stain
intensity at magnifications of 134X and 334X and the density of neurons and processes was
quantified using the threshold and intensity functions. The total intensity of the MAP-2 stain
was recorded and the area occupied by MAP-2 immunoreactive cell bodies and processes
was measured and expressed as a percentage of the entire field. Background stain intensity
was measured in regions that did not contain neurons and was negligible.
LM11A-31: a non-peptide neurotrophin ligand
The compound LM11A-31 was initially identified by Drs. Longo and Massa using a virtual
screen of a small molecule library to identify compounds mimicking the spatial and physical
chemical features of the loop 1 region of NGF, a domain known to bind to p75NTR(Massa et
al., 2002). Subsequent screening of compounds showed LM11A-31 to have neurotrophic
activity, high affinity for p75NTR, and the ability to activate downstream signaling via PI3
kinase and Akt(Massa et al., 2006; Massa et al., 2002) with no direct actions on the nerve
growth factor receptor, TrkA or the brain-derived neurotrophic factor (BDNF) receptor,
TrkB. LM11A-31, has potent neuroprotective properties in mouse hippocampal cultures
under conditions of serum starvation with EC50 values of 200–300 pM and a maximally
effective concentration of 5–100 nM in various assays(Massa et al., 2006; Yang et al.,
2008). In rat and feline neural cultures, a concentration of 10 nM was shown to be optimal to
promote survival under a variety of conditions.
Calcium imaging
Neuronal cultures were washed in HEPES-buffered artificial CSF (aCSF, concentrations in
mM: NaCl 137, KCl 5.0, CaCl2 2.3, MgCl2 1.3, glucose 20, HEPES 10, adjusted to pH 7.4
with NaOH) and pre-loaded with the calcium indicator, Fluo-4 AM using the Molecular
Probes Fluo-4 NW Calcium Assay Kit (Molecular Probes/Invitrogen, Eugene, OR) at a 1:4
dilution. After 30 minutes the coverslip was mounted in a specialized stage for imaging
(Warner Instruments, Hamden, CT). LM11A-31 was added to the coverslips in the chamber
to allow approximately 10 min exposure prior to the challenge. The cells were challenged
with conditioned medium from feline macrophages infected with FIV. The toxic challenge
was added in a volume of 80 μl to 320 μl aCSF in the chamber to provide a 1:5 dilution of
the stock. Neural cultures stimulated with aCSF were used to establish the non-toxic
reference baseline and the pre-inoculation conditioned medium was used to establish basal
activity of the macrophages.
Time lapse digital images were captured automatically by the Metamorph System
(Molecular Devices, Union City, CA). Three pre-stimulation measurements were taken to
establish basal levels of fluorescence at the beginning of each experiment. Acute changes in
calcium were measured at 0.1 min intervals for 6 min. Delayed changes in calcium were
measured at 1 min intervals for an additional 60 min. The increase in fluorescence intensity
(free calcium) within each cell was then measured relative to the baseline measurements to
correct for cell to cell differences in dye loading and intrinsic fluorescence. Responses to
each challenge were also compared to runs with aCSF and/or control medium and corrected
for non-specific effects if necessary. In most cases the background changes were negligible.
Medium that caused a pronounced late destabilization of intracellular calcium was defined
as toxic and was used as the challenge against which the actions of LM11A-31 were
assessed.
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FIV infection of feline neural cultures
Addition of FIVV1CSF and FIVNCSU1 to primary feline neural cultures at biologically
relevant levels of 104 – 106 TCID50/ml had no significant acute effect but led to a gradual
appearance of dendritic beading, pruning and neuronal shrinkage. Cultured feline neurons
inoculated with FIV and stained for MAP-2 after 7 days are illustrated in Figure 1.
Untreated neurons (Fig 1A) had excellent outgrowth of dendrites and well stained cell
bodies. One week after inoculation with FIV, the dendrites show early signs of beading
(small arrows), simplification of the dendrites (open arrow) and shrinkage with very thin or
poorly stained cytosol (large arrow). The loss of the dendritic architecture in particular leads
to an overall reduction in MAP-2 staining which can be used to assess the extent of damage.
The time course for the development of damage based on the mean MAP-2 stain intensity is
illustrated in Figure 1C. At 3 days post-inoculation, no changes are seen. At seven days
post-inoculation there is a 57% loss of MAP-2 stain intensity (p=0.0049, FIV vs.
uninoculated) and by 14 days a 77% loss (p=0.0003 FIV vs. uninoculated).
LM11A-31 provides neurotrophic support to feline neurons
To establish the neurotrophic properties of LM11A-31, cat neurons were seeded at a very
low density and half the cultures were treated with 10 nM LM11A-31 in the medium. Initial
seeding density was matched within each run at approximately 2800–4000 cells/cm2 and
cultures were fed every two days with complete MEM or MEM+LM11A-31. Neuron
survival is typically poor at these low densities in the absence of additional neurotrophic
support. Three days after seeding, neuron survival was significantly higher in the
LM11A-31 treated cultures (Figure 2A). After fourteen days of treatment with LM11A-31,
neurons exhibited a 6.6-fold increase in the total MAP-2 stained area (Figure 2B) which
reflects both the density of neurons and extent of process outgrowth.
LM11A-31 reduces FIV-associated damage
To test the effects of LM11A-31 in the presence of FIV, feline neural cultures at 12 days in
culture were inoculated with 105 TCID50 FIV mix followed immediately by addition of
LM11A-31 at a concentration of 10 nM. LM11A-31 was sustained in the culture throughout
the experiment and the cells were fixed at 3 and 7 days post-treatment and stained for
MAP-2 and GFAP. The FIV inoculated cultures showed damage after seven days which is
illustrated in Figure 3A. Beading and simplification of MAP-2+ processes and neuron
shrinkage was seen as in Figure 1 and a co-stain for GFAP stain also showed a retraction of
astrocyte processes with development of a more process bearing morphology. Treatment
with LM11A-31 reversed much of this damage with most cultures showing healthy neurons
with elaborate processes on a more uniform bed of astrocytes (Figure 3B). Quantification of
the MAP-2 stain shown in Figure 4, illustrates the mean (± sem) MAP-2 fluorescence
intensity relative to untreated control cultures at three days and seven days post-inoculation.
At three days no decrease in MAP-2 stain or changes in neuron morphology were seen (94.8
± 7.1% of control) and by seven days a 58% decrease was seen (41.8 ± 15.7% of control,
p=0.0049). In each case, treatment with LM11A-31 resulted in MAP-2 staining that was
above the control values (172–193%) and 4-fold greater than the MAP-2 intensity of the
neural cultures treated with FIV (FIV+LM11A-31 vs. FIV at 7 days, p=0.0111).
To evaluate the relative effect of FIV on dendrites and cell bodies, the MAP-2 stained area
was quantified in cultures treated for seven days with FIV (Figure 4B, C). MAP-2 stained
dendrites accounted for an average of 82 ± 4% of the stained area or 4.6 times the area of the
neuron cell bodies. Figure 4B shows the large reduction in stained dendrites in the presence
of FIV. Treatment with 10 nM LM11A-31 prevented the loss of dendrites (p<0.001). The
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decrease in the neuronal perikarya is illustrated in Figure 4C. FIV induced a 40% reduction
in the cell body area. This loss was partially reversed by LM11A-31 but did not reach
significance. The distribution of neuron perikarya areas is illustrated in Figure 4D. Control
neurons have a broad distribution of sizes from about 150 to 350 μm2 likely reflecting
different types. In the presence of FIV neurons tend to shift to a single distribution similar to
the smaller control neurons. Treatment with LM11A-31 pushes the distribution significantly
to the right again reflecting a broader distribution (X2 = 27.49, 6 df, p <0.01) that begins to
resemble the control cell distribution. The neuron density in these same cultures did not
change significantly between conditions: 150.6 ± 20.2, 143.8 ± 18.5 and 155.3 ± 16.6
neurons/mm2 for untreated controls, FIV and FIV+LM11A-31, respectively. LM11A-31-
associated recovery was significant at FIV titers of 104–106 TCID50/ml but decreased in
magnitude to 56% at the highest viral load (Figure 5).
FIV associated changes in astrocytes and microglia
After inoculation of the neural cultures notable changes were seen in both astrocytes and
microglia. The morphology of the astrocytes often became less flattened with a more fibrous
appearance as illustrated in Figure 3. In cultures showing the greatest damage, the retraction
of astrocyte processes was often more severe. An analysis of the density of GFAP+
astrocytes in the cultures, however, showed only a small (12% p=0.0631), non-significant
decrease in the mean area occupied by the astrocytes.
Increased numbers of microglia were observed in the cultures treated with FIV particularly
at the longer durations. In neural cultures inoculated at day 6–8 with FIV microglial density
is initially very low (1.8 ± 1.2 microglia/mm2; 0.8% of the neuron density). Seven days after
inoculation when damage is evident, the density of microglia increased to 12.4 ± 0.7/mm2, a
small (~5% of the neuron density) but significant increase (p=0.0170). In contrast, between
seven and 16 days the density of microglia increased dramatically to 918 ± 83/mm2. To
determine if treatment with LM11A-31 influenced the accumulation of microglia we labeled
the microglia with 2 μg/ml DiI acetylated LDL and counted the number in five fields/
culture. We started with matched cultures with visible microglia (day 12 in vitro) and
measured the microglial density/mm2 at 7 days post-inoculation (day 19 in vitro). As
illustrated in Figure 6A, FIV induced a significant increase in microglia which was reversed
in the presence of LM11A-31. To determine if the increase was a direct effect of FIV on the
microglia in the relative absence of neurons, enriched microglial cultures were prepared and
challenged with FIV or FIV+LM11A-31. As illustrated in Figure 6C, inoculation of isolated
microglia with FIV or FIV+LM11A-31 failed to show any changes in microglial density.
Similar effects were seen in cultures with a lower initial density of purified microglia (not
shown). Quantification of microglial death (Figure 6D) also showed little death (0.2–0.6%)
and failed to show any significant changes due to the treatments.
LM11A-31 suppresses the neuronal calcium destabilization and damage in response to
macrophage conditioned medium
To recapitulate FIV neuropathogenesis in vitro we used medium collected from feline
choroid plexus macrophages 3 days after infection with 106 TCID50/ml FIV. The FIV dose
was chosen to provide a robust response with no observable damage to the cells. When
applied to feline neurons, the FIV-challenged feline macrophage conditioned medium
(fMCM) produces a rapid increase in intracellular calcium followed by a late destabilization
of calcium. Dendritic beading and pruning appear during the late destabilization (Figure 7A)
but show early signs of destabilization and swelling as early as 5.8 minutes after stimulation.
Neurons challenged with the same conditioned medium in the presence of 10 nM
LM11A-31 (Figure 7B) failed to show the delayed destabilization of calcium even when the
initial calcium rise was matched to the FIV cultures (Figure 7, 0.5 Min). In the absence of
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the delayed calcium rise, dendritic swelling or other signs of damage at 66 min were
minimal or absent. The mean calcium response of feline neurons exposed to fMCM is
illustrated in Figure 8A. After a slight delay, the macrophage conditioned medium induced a
rapid rise in calcium which did not recover. After 6–10 min, a progressive increase in
calcium was seen. In the presence of LM11A-31 the acute rise was similar but there was no
late destabilization of calcium. Values were corrected for the effects of medium alone which
induced a small acute rise in calcium (+65 fluorescence units) and a gradual upward drift in
the delayed phase (+96 fluorescence units). Calcium levels remained stable throughout the
experiment in cells challenged with aCSF.
Although these cultures are highly enriched in neurons, a small number of astrocytes were
present which allowed a parallel evaluation of the astrocyte calcium responses. The average
astrocyte response to the conditioned medium, illustrated in Figure 8B, was about 25% of
the neuronal response in the acute phase and 9% in the delayed phase. However, the
astrocytes showed varied response patterns. Most exhibited only a very small gradual
increase in intracellular calcium above baseline as illustrated for a typical cell in Figure 8C.
A subpopulation of astrocytes exhibited multiple brief spikes of calcium in the delayed
phase in response to the conditioned medium. The typical pattern is illustrated in Figure 8D
where repetitive spikes are seen after about 20 min. There was little synchrony of the
patterns between cells and the onset was almost always after destabilization was seen in the
neurons. Untreated astrocytes would also occasionally show an isolated spike of activity as
illustrated in a cell exposed to aCSF (arrow), but this was rare relative to the challenged
cells.
FIV production in the presence of LM11A-31
Peripheral blood mononuclear cell (PBMC), macrophage and microglial cultures were
infected with an FIV mix at an MOI of 1 in the presence or absence of 10 nM LM11A-31.
The cultures were washed at four hours and FIV was measured in the medium every 3 days
over a period of 21 days. Cumulative FIV production from 6 to 21 days was calculated to
compensate for any variation in the timing of FIV expression and is illustrated as mean log
cumulative FIV ± sem (n=3) in Figure 9. No difference was seen in FIV content in the
PBMC cultures. LM11A-31 was associated with a slight increase in FIV in the macrophage
cultures and a very slight decrease in the microglial cultures, neither of which was
significant.
Discussion
Feline neural cultures inoculated with FIV or treated with medium from FIV-infected
macrophages develop pathological changes such as dendritic beading and pruning that are
thought to reflect the underpinnings of HIV-associated neural dysfunction. These changes
are preceded by the destabilization of neuronal intracellular calcium. Since this pathological
sequence is likely to reflect changes that initiate HIV neuropathogenesis in vivo, it provides
an opportunity to explore the actions of putative therapeutic compounds in a model that
should translate to natural infection. The current studies provide the first assessment of a
novel neuroprotective neurotrophin ligand with this model. Deficits in neurotrophins have
been reported in HIV-infected patients suggesting a loss of protective neurotrophin
signaling. LM11A-31 is a novel ligand that penetrates the blood-brain barrier and mimics
the protective actions of NGF at the p75NTR. It competes with NGF for high affinity binding
and triggers the activation of Akt and neurite outgrowth (Massa, 2006). Thus, it has the
potential to improve neurotrophin signaling and protect against virus-associated damage.
Neurotrophic activity of LM11A-31 was demonstrated in these studies by showing enhanced
feline neuron survival and outgrowth at low seeding densities. Enhanced neuronal outgrowth
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was substantial after 2 weeks of treatment illustrating both the long-term beneficial effects
of the compound as well as the absence of toxicity.
The suppression of damage from infectious FIV in these cultures at nanomolar
concentrations further illustrated the potential utility of this compound for prevention of
FIV-associated neural damage. No significant changes were seen in FIV replication
although a very small effect was seen on macrophage FIV synthesis in agreement with
Souza, et al. (Souza et al., 2011). Although this will have to be verified in vivo, these
observations indicate that LM11A-31 can be used in infected cats with minimal risk of
accelerating viral replication. The neuroprotective effect of LM11A-31 was most prominent
on the elaboration of dendrites, consistent with neurotrophic actions. Treatment of FIV
infected cultures with 10 nM LM11A-31 completely restored the average neuronal dendritic
tree with no significant changes in the density of neurons under any condition. The putative
shrinkage of neurons was partially reversed by LM11A-31 with a significant change in the
size distribution toward larger sizes similar to controls. The protective effect was almost
complete for the primary endpoint of MAP-2 stained area except at the highest viral burdens
and with severe challenges such as combinations of concentrated macrophage toxins and
glutamate (not shown). Thus, LM11A-31 offered protection over a wide range of toxic
activity and had diminished efficacy only under highly toxic conditions.
It is noteworthy that the inoculation of the cultures with FIV also triggered an accumulation
of microglia and changes in astrocyte morphology. The accumulation of microglia could
certainly contribute to pathogenesis by increasing the number ot toxin-producing cells. The
suppression of microglial accumulation by LM11A-31 could contribute to neuroprotection
but several observations indicate that this effect was not the primary action responsible for
the neuroprotection. The high accumulation of microglia was apparent only in the cultures
with longer exposures to FIV. The accumulation was still relatively low after 7 days when
damage was readily apparent suggesting that the increase may be secondary to neural
damage. In addition, the effects of LM11A-31 in low density cultures and in the calcium
assays were seen in the almost complete absence (<1%) of microglia. The potential impact
of LM11A-31 interactions with the microglia remains an open question. Neurotrophin
receptors have been identified on monocytes and macrophages raising the possibility of
direct actions of LM11A-31 on cells of monocyte lineage(Dowling et al., 1999; Barouch et
al., 2001; Samah et al., 2008). The role of neurotrophins in the regulation of microglia is
poorly understood and this is an important area for future studies. In contrast to the
microglia, the change in astrocyte morphology was not paralleled by a significant decrease
in average GFAP+ astrocyte density. A very small increase in intracellular calcium was seen
in the astrocytes in response to macrophage conditioned medium which was largely due to
small bursts of activity in a subpopulation of cells. The increase was suppressed by
pretreatment with LM11A-31. The bursts of activity typically appeared late in the run, after
the onset of calcium accumulation and dendritic swelling in the neurons. Thus, like the
microglia we believe the response of the astrocytes may be secondary to changes in the
neurons. Each of these cells probably play a role at various stages of FIV pathogenesis and
more work is needed to better understand the interactions that either drive pathogenesis or
support recovery.
An important observation was the demonstration of the ability of LM11A-31 to inhibit the
acute calcium rise and delayed calcium destabilization in neurons in response to conditioned
medium from FIV-treated feline macrophages. Exposure to macrophage toxins(Giulian et
al., 1990; Pulliam et al., 1991; Kaul et al., 2001) and the disruption of calcium
homeostasis(Dreyer et al., 1990; Haughey et al., 1999; Holden et al., 1999; Meeker et al.,
1999; Bragg et al., 2002; Meeker, 2007) are considered important early events in the
development of neural damage. Indeed the calcium rise typically preceded the development
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of visible pathology. FIV alone added to the neural cultures did not produce a similar effect.
This reinforced the idea that the interaction of FIV with the macrophages is instrumental in
the development of the toxic response. The mechanisms responsible for the calcium rise and
the protective effects of LM11A-31 are not completely understood. The relationship
between p75NTR signaling and calcium homeostasis is also unknown but is likely to be
indirect. The destabilization of calcium in this model and the development of damage
resemble excitotoxicity (Tymianski et al., 1993) but are also different in important ways.
First, unlike excitotoxic challenges where the strong initial activity is thought to drive the
delayed calcium deregulation, the deregulation in our experiments was unrelated to the acute
rise in calcium. Our previous studies suggested a dysfunction of the sodium-calcium
exchanger (NCX) may contribute to the calcium dysregulation(Bragg et al., 2002; Meeker et
al., 2005). The role of forward and reverse calcium exchange in different settings is still
controversial (Bano et al., 2005; Brustovetsky et al., 2010) and the relationship between the
calcium dysregulation and structural pathology is unclear. Various hypotheses have
implicated dysfunctional mitochondria (Greenwood et al., 2007), loss of actin
structure(Zeng et al., 2007) or disruption of neurofilaments (Kim et al., 2010). By activating
Akt and targeting early events in the pathogenesis, LM11A-31 may suppress destructive
events at many levels. More studies are needed to precisely identify the molecular pathways
that lead to neuronal dysfunction and the role of neurotrophin receptors in the control of
these pathways.
The use of the FIV model for the development of a new therapeutic strategy has set the stage
for efficient translation to an in vivo model. The FIV model will continue to provide
important resources for the evaluation of interactions between LM11A-31 and FIV under
both in vitro and in vivo conditions. Exploration of these interactions with various cell types
will help to define the therapeutic and non-therapeutic actions of neurotrophin ligands.
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Example of early FIV-induced damage to feline neurons in vitro. A. In the absence of FIV,
isolated MAP-2 immunoreactive feline neurons (green) exhibit large cell bodies with
elaborate outgrowth of dendrites on a uniform bed of GFAP+ astrocytes (red). B. Seven
days after inoculation with 105 TCID50 FIV, neurons often appear shrunken with thin
cytosol (large arrow), dendrites show early signs of beading (small arrows) and otherwise
healthy neurons show a simplification of processes (open arrow). C. Mean ± sem MAP-2
immunoreactivity at various times after inoculation with FIV. No loss was seen over the first
3 days after which MAP-2 immunoreactivity decreased to 43% of uninfected controls by 7
days and 23% at 14 days (p=0.0049, n=6 and 0.0003, n=4, respectively relative to
uninoculated controls).
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LM11A-31 supports survival of feline neurons in low density cultures. Feline neurons were
cultured at a density of 23–40 cells/mm2 in the presence or absence of 10 nM LM11A-31.
A. Three days after seeding, untreated neurons were present at an average (± sem) density of
13.7/mm2 (34.2% survival) whereas in the presence of LM11A-31 a significantly higher
density of 22.9/mm2 (57.3% survival) was seen (p=0.0110 LM11A-31 vs. untreated, n=12
cultures each). B. A significant effect of LM11A-31 was also seen in the outgrowth of
neurons after 14 days of continuous treatment. An average of 3.6% of the culture surface
was occupied by MAP-2 immunoreactive cells and processes in the LM11A-31 cultures
relative to 0.86% in the untreated cultures (p=0.039 LM11A-31 vs. untreated, n= 6 cultures
each).
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LM11A-31 prevents damage to neurons inoculated with FIV. A. Example of neuronal
damage seen after 7 days exposure to FIV. Beading, pruning and shrinkage is evident in
MAP-2 stained neurons (green) with a shift toward development of process bearing GFAP-
positive astrocytes (red). Nuclei were stained blue with bisbenzimide. B. Concurrent
addition of 10 nM LM11A-31 to the FIV-inoculated cultures resulted in a preservation of
neuron integrity on a normal bed of astrocytes.
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Quantification of MAP-2 staining relative to untreated controls at 3 and 7 days post-
inoculation. A. At 3 days no significant change in average MAP-2 fluorescence intensity
from controls was seen whereas by 7 days a 52% decrease was seen (p=0.0049 vs. untreated,
n= 6 each). Values are normalized to controls (100%). The FIV-associated decrease in
MAP-2 immunoreactivity was completely reversed in the presence of 10 nM LM11A-31
(p=0.0111, FIV vs. FIV+LM11A-31, n=6 each) to a value that was 172% of untreated
controls. B. Measurement of the area occupied by MAP-2 stained dendrites at 7 days
indicated that the effects of FIV were largely due to a decrease in the dendritic architecture
(p=0.00079, n=16) with almost complete prevention of the loss by 10 nM LM11A-31
(p=0.00004, n=11). C. The area of neuronal cell bodies also decreased significantly at 7 days
(p=0.0017, n=16) in the FIV-infected cultures but was only partially reversed by LM11A-31
(n=11). D. Characterization of the distribution of neuron cell body areas illustrated that
LM11A-31 significantly shifted the distribution toward a broader profile with larger cells
(X2 =27.5, df=6, p<0.01, 198–244 neurons), similar to untreated neurons.
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LM11A-31 efficacy varies with FIV load. FIV titers of 104, 105 and 106 TCID50/ml
produced similar decreases in MAP-2 staining intensity. Addition of 10 nM LM11A-31
resulted in a significant recovery of MAP-2 in each case but the extent of recovery
decreased from 172% (n=6) to 123% (n=7) and 56% (n=10) as the amount of FIV increased.
Values are normalized to controls (100%).
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Microglial changes in response to FIV and LM11A-31. A. Neural cultures inoculated with
105 TCID50 FIV showed a significant increase in microglia after 7 days (p=0.0148, FIV vs.
Control, n=15 and 11, respectively) which was largely reversed in the presence of 10 nM
LM11A-31 (p=0.0297, FIV vs. FIV+LM11A-31, n=15 and 14, respectively). B. Large
increases in microglia typically appeared after prolonged exposure to FIV. A significant
increase in microglia was seen seven days post inoculation (Day 7 p.i., n=23) but numbers
were still very low relative to neurons in the culture (~5% of the neuron density). By day 16
post-inoculation (n=10), microglia were abundant. C. Inoculation of microglia enriched
cultures with FIV or treatment with LM11A-31 in the relative absence of neurons failed to
affect density (n=4–6 cultures each). D. Inoculation of enriched microglia enriched cultures
with FIV or treatment with LM11A-31 - did not produce significant microglial death (0.2–
0.6%, n=4–6 cultures each).
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Feline macrophage conditioned medium (fMCM) from FIV-inoculated macrophages (106
TCID50/ml) induced a destabilization of intracellular calcium that was inhibited in the
presence of LM11A-31. Conditioned medium from feline choroid plexus macrophages
collected 3 days after inoculation with FIV was applied to primary feline neurons at a
dilution of 1:5 in aCSF. Fluorescence intensity (calcium concentration) is pseudocolored to
highlight changes (white>red>yellow>green>blue>dark blue). A. The conditioned medium
caused a modest acute rise in intracellular calcium (0.5 min) which failed to recover leading
to the appearance of focal calcium increases and swelling in dendrites by 5.8 min followed
by a large calcium destabilization and dendritic beading after 66 min. B. Cultures pre-treated
with 10 nM LM11A-31 for 10 min and challenged with the same feline macrophage-
conditioned medium as above showed a similar acute rise but minimal delayed
destabilization.
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Summary of the mean ± sem calcium changes (Fluorescence Increase) in response to fMCM
or fMCM+LM11A-31. A. After a brief delay, fMCM (solid circles, n=119 neurons) induced
a rise in calcium with no recovery over the first 6 min. A gradual destabilization of calcium
developed over the next 60 min giving rise to high intracellular calcium. Co-stimulation
with LM11A-31 did not change the acute calcium rise but largely prevented the
destabilization (n=114 neurons). Neurons treated with aCSF (n=101 neurons) showed stable
calcium levels throughout illustrating the integrity of the neurons in the absence of
stimulation. B. Astrocytes (n=60) in the same cultures as A showed small increases in
intracellular calcium (note change in scale versus A) but minimal long-term destabilization.
The addition of LM11A-31 (n=58) suppressed the calcium changes to near background
(aCSF) levels. C. Example of the typical calcium profile of most astrocytes showing
negligible acute and small long-term changes relative to aCSF controls. D. Example of
calcium responses seen in a subset of astrocytes which showed pulses of calcium during the
delayed phase. This activity was not synchronized between astrocytes and occurred after the
appearance of calcium elevations in the neurons.
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Recovery of FIV from PBMCs, choroid plexus macrophages or microglia inoculated with
FIV at an MOI of 1. Log cumulative FIV recovery from day 6 to day 21 in culture was
calculated and the mean ± sem values (n=3 cultures each) plotted. FIV replication in
PBMCs was the same in the presence or absence of LM11A-31. A small but non-significant
increase was seen in macrophages treated with LM11A-31. A very small non-significant
decrease was seen in microglia.
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